Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1 - 25 of 650 in total

Naxitamab

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved
Matched Synonyms: … Monoclonal antibody HU3F8 ... Anti-Gd2 monoclonal antibody 3F8 humanized ... Humanized monoclonal antibody HU3F8-IGG1 …
Matched Description: … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation ... [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of ... naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent …
Matched Categories: … Glycolipid Disialoganglioside-directed Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Glycolipid Disialoganglioside-directed Antibody Interactions …

Retifanlimab

Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Synonyms: … Anti-PD-1 monoclonal antibody MGA012 …
Matched Description: … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Synonyms: … Anti-CD20/CD3 bispecific monoclonal antibody RO7082859 …
Matched Description: … Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface ... refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20/CD3 bispecific monoclonal antibody …

Loncastuximab tesirine

Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
Approved
Investigational
Matched Synonyms: … Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through …
Matched Description: … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Talquetamab

Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. Talquetamab binds to GPRC5D, a cell surface...
Approved
Investigational
Matched Synonyms: … 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY ... 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY …

Infliximab

Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in...
Approved
Matched Description: … Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody …

Brolucizumab

Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
Approved
Investigational
Matched Description: … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat …

Dimercaprol

Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past...
Approved

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. ... It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic ... L12612] Although it has a similar molecular mechanism of action as [rituximab], another CD-20 monoclonal antibody …
Matched Categories: … CD20-directed Cytolytic Antibody ... CD20-directed Antibody Interactions ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the...
Approved
Investigational
Matched Description: … Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from ... [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some ... yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody …
Matched Categories: … CD38-directed Cytolytic Antibody ... CD38-directed Antibody Interactions ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. ... [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody …
Matched Categories: … CD3-directed Antibody Interactions ... CD20-directed Antibody Interactions …

Obinutuzumab

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to …
Matched Categories: … CD20-directed Cytolytic Antibody ... CD20-directed Antibody Interactions ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against …
Matched Categories: … CTLA-4-directed Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Description: … Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. ... It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …

Raxibacumab

Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Approved
Matched Description: … Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of …
Matched Categories: … Anthrax Protective Antigen-directed Antibody ... Anthrax Protective Antigen-directed Antibody Interactions …

Ocrelizumab

Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ocrelizumab is...
Approved
Investigational
Matched Description: … Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary ... [L42895] It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets …
Matched Categories: … CD20-directed Cytolytic Antibody ... CD20-directed Antibody Interactions …

Rituximab

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally...
Approved
Matched Description: … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the ... The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region …
Matched Categories: … CD20-directed Cytolytic Antibody ... CD20-directed Antibody Interactions ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ipilimumab

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
Approved
Matched Description: … Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 …
Matched Categories: … CTLA-4-directed Blocking Antibody ... CTLA-4-directed Antibody Interactions ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Nivolumab

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 ... [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …

Basiliximab

A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell...
Approved
Investigational
Matched Description: … A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive ... chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody …
Matched Categories: … Interleukin-2 Receptor Blocking Antibody ... Interleukin 2 Receptor-directed Antibody Interactions …

Ibritumomab tiuxetan

Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and...
Approved
Investigational
Matched Description: … Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, …
Matched Categories: … CD20-directed Antibody Interactions ... CD20-directed Radiotherapeutic Antibody …

Fremanezumab

Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide …

Alemtuzumab

Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a...
Approved
Investigational
Matched Description: … Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. ... complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). ... It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the …
Matched Categories: … CD52-directed Cytolytic Antibody ... CD52-directed Antibody Interactions …

Ciltacabtagene autoleucel

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational

Inebilizumab

Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning ... [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against ... Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader …
Matched Categories: … CD19-directed Cytolytic Antibody …
Displaying drugs 1 - 25 of 650 in total